C-Suite Speaks

The Japanese pharma specialist has embarked on an ambitious journey to become a global specialty pharmaceutical company, driven by its first non-Japanese president at the helm.

Lithuania is betting big on life sciences to drive 5% of its GDP by 2030. In Vivo speaks to local innovators, who are the driving force of the country’s vision.

Aviv Regev is betting AI-driven drug discovery can transform Genentech's pipeline, with early wins validating her computational biology approach to pharmaceutical R&D.

Essential Pharma CEO Emma Johnson discusses the company’s strategic priorities and plans for growth as it expands its portfolio in rare diseases.

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.

2026 is positioned as a breakout year for the psychedelic therapeutics sector, with multiple players expected to deliver defining Phase III results – creating momentum across the industry.

The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

In the near future, “the US may no longer hold its position as the most important market,” says the CEO of a UK-based emerging biotech firm. Today’s biotech companies are shifting their growth strategies dramatically – moving away from reliance on a single dominant market.

Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.